Avoid common mistakes on your manuscript.
Text
In our recent article [1], we did not declare the patent rights related to stampidine technology. Since they may potentially be viewed as non-financial competing interests despite the fact our employer is a non-profit public charity, we are now providing the following supplemental information:
FMU, AOV and HET are employees of Parker Hughes Institute, which has applied for a patent for the use of stampidine in the treatment of haemorrhagic fever. Parker Hughes Institute currently holds patents for the use of stampidine in other clinical conditions, with FMU listed as an inventor.
References
Uckun FU, Petkevich AS, Vassilev AO, Tibbles HE, Titov LP: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect Dis. 2004, 4: 1-10.1186/1471-2334-4-1.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/4/14/prepub
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at 10.1186/1471-2334-4-1
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Uckun, F.M., Petkevich, A.S., Vassilev, A.O. et al. Erratum to: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect Dis 4, 14 (2004). https://doi.org/10.1186/1471-2334-4-14
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/1471-2334-4-14